# VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia

> **NCT00291187** · PHASE3 · COMPLETED · sponsor: **Vanda Pharmaceuticals** · enrollment: 411 (actual)

## Conditions studied

- Insomnia

## Interventions

- **DRUG:** 20 mg VEC-162
- **DRUG:** 50 mg VEC-162
- **DRUG:** 100 mg VEC-162
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00291187
- **Lead sponsor:** Vanda Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2006-08
- **Final completion:** 2006-08
- **Target enrollment:** 411 (ACTUAL)
- **Last updated:** 2014-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00291187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00291187, "VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia". Retrieved via MORVS 2026-10-16 from https://api.morvs.ai/clinical/NCT00291187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*